Phathom Pharmaceuticals Accelerates EoE Trial Enrollment with Vonoprazan
Event summary
- Phathom Pharmaceuticals completed patient enrollment in its Phase 2 pHalcon-EoE-201 study for VOQUEZNA® (vonoprazan) in eosinophilic esophagitis (EoE), ahead of schedule.
- The trial enrolled 95 patients across 41 U.S. sites, making it the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE.
- Topline results from the double-blind 12-week treatment portion are expected in Q4 2026.
- If successful, the study could inform future development strategies for vonoprazan in EoE, including potential pediatric evaluation.
The big picture
Phathom Pharmaceuticals' accelerated enrollment in the Phase 2 pHalcon-EoE-201 study highlights its strategic focus on expanding vonoprazan's indications beyond its current approvals. The trial's success could position vonoprazan as a novel, non-steroidal treatment option for EoE, addressing an unmet need in a growing indication. The potential for pediatric evaluation adds another layer of strategic value, possibly extending regulatory exclusivity.
What we're watching
- Clinical Efficacy
- Whether vonoprazan demonstrates superior efficacy compared to existing treatments in the Phase 2 trial results.
- Regulatory Pathway
- How the FDA may respond to potential future development plans for vonoprazan in EoE, including pediatric evaluation.
- Market Positioning
- The pace at which Phathom can position vonoprazan as a non-steroidal treatment option for EoE if the trial is successful.